Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Behaviors and Mental Disorders

Infections

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Stomach Neoplasms

Prostatic Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Lung Neoplasms

Carcinoma, Hepatocellular

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Esophageal Neoplasms

Lymphoma

Triple Negative Breast Neoplasms

Uterine Cervical Neoplasms

Melanoma

Carcinoma, Renal Cell

Microsatellite Instability

Carcinoma, Transitional Cell

Lymphoma, Follicular

Lymphoma, B-Cell

Aggression

Carcinoma, Merkel Cell

Stomach Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Esophageal Cancer

Lymphosarcoma

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Follicular Lymphoma

B-cell Lymphoma

Merkel Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL

Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL

Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.

Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.

The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.

VIP152 (BAY 1251152)

30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.

VIP152 (BAY 1251152) 30 mg

200 mg IV fixed dose once every 3 weeks of a 21 day cycle

Keytruda

The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.

VIP152 (BAY 1251152) 15 mg

Vincerx Study Director

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).

Part 2 VIP152 Monotherapy (Global). Part 3 dose escalation with VIP152 in combination with pembrolizumab (US only). Part 4 dose expansion with VIP152 in combination with pembrolizumab (US only).

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.

Vincerx Pharma, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer	NCT02635672	Neoplasms	VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125...	18 Years -	Vincerx Pharma, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer	NCT02635672	Neoplasms	VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125...	18 Years -	Vincerx Pharma, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer	NCT02635672	Neoplasms	VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125...	18 Years -	Vincerx Pharma, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer	NCT02635672	Neoplasms	VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125...	18 Years -	Vincerx Pharma, Inc.

Spots Global Cancer Trial Database for vip152 (bay 1251152) 15 mg